Evaluation of Commercial Molecular Diagnostic Methods for Detection and Determination of Macrolide Resistance in Mycoplasma pneumoniae
Sixto M. Leal, Arthur H. Totten, Li Xiao, Donna M. Crabb, Amy E. Ratliff, Lynn B. Duffy, Karen B. Fowler, Emily Mixon, Jonas M. Winchell, Maureen H. Diaz, Alvaro J. Benitez, Bernard J. Wolff, Xuan Qin, Yi‐Wei Tang, Mark D. Gonzalez, Rangaraj Selvarangan, Tao Hong, Edward G. Brooks, Steve Dallas, T. Prescott Atkinson, Xiaotian Zheng, Jennifer Dien Bard, Ken B. Waites
Abstract
We evaluated six commercial molecular tests targeting Mycoplasma pneumoniae , namely, the BioFire FilmArray respiratory panel (RP), the Meridian Alethia Mycoplasma Direct, the GenMark ePlex respiratory pathogen panel (RPP), the Luminex NxTAG RPP, the ELITech ELITe InGenius Mycoplasma MGB research use only (RUO) PCR, and the SpeeDx Resistance Plus MP assays. Laboratory-developed PCR assays at the University of Alabama at Birmingham and the Centers for Disease Control and Prevention were used as reference standards.